Discovery of novel PCFT-targeted agents
新型 PCFT 靶向药物的发现
基本信息
- 批准号:8103512
- 负责人:
- 金额:$ 46.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2016-02-28
- 项目状态:已结题
- 来源:
- 关键词:4-Aminobenzoic AcidAffinityAnabolismAnionsAntineoplastic AgentsBindingBiologicalBloodBone MarrowCell LineCell ProliferationCellsChinese HamsterCollaborationsCoupledCytotoxic agentCytotoxinDiffusionDrug DesignDuodenumEngineeringEnzymesEvaluationExhibitsFolateFolic AcidFolic Acid AntagonistsFormatesGenerationsGlutamatesGlycineGoalsGrowthHamstersHomeostasisHumanHydroxymethyltransferasesImplantIn SituIn VitroInstitutionIntestinesKidneyLabelLeadLeucovorinLigaseLiverMalignant NeoplasmsMammalian CellMediatingMembraneMembrane Transport ProteinsMetabolicMetabolismMethotrexateModelingModificationMolecularMolecular ModelsMolecular ProfilingMolecular TargetMonitorNon-Small-Cell Lung CarcinomaNormal CellNucleosidesNucleotide BiosynthesisOvarian CarcinomaOvaryPatternPemetrexedPharmaceutical PreparationsPharmacologyPhysiologicalPrimary carcinoma of the liver cellsPropertyProtonsPteridinesPurine NucleotidesPurinesRadiolabeledRaltitrexedReportingResearch PersonnelReverse Transcriptase Polymerase Chain ReactionRibonucleotidesRoleRouteSCID MiceSLC19A1 geneSeriesSolid NeoplasmSpecificityStructureStructure of choroid plexusStructure-Activity RelationshipSystemTestingTetrahydrofolatesTherapeuticThymidylate SynthaseThymidylate Synthase InhibitorTimeTissuesToxic effectTransmembrane TransportTumor Cell Lineabsorptionanalogantitumor agentbasebrush border membranecancer therapychemotherapycytotoxiccytotoxicityefficacy trialexperiencefolate-binding proteinglycine amidehepatoma cellhuman tissuein vivoinhibitor/antagonistinterstitialleukemialung Carcinomamolecular modelingneoplastic cellnovelpharmacophorepolyglutamatespurineradiotracersmall moleculesubcutaneoustherapeutic targettumoruptake
项目摘要
DESCRIPTION (provided by applicant): In recent years, there has been renewed emphasis on folate-based therapeutics for cancer based on capacities for tumor-selective membrane transport. This application explores the therapeutic potential for the human proton-coupled folate transporter (hPCFT), a recently discovered membrane transport system for folates and antifolates which is functionally and (to some degree) anatomically distinct from the ubiquitously expressed reduced folate carrier (RFC), the major tissue folate transporter. We hypothesize that hPCFT represents a novel and selective means for therapeutic targeting small molecule cytotoxins that are not transported by RFC. This concept is based on frequent and high level hPCFT expression in many human solid tumors, the acidic pH optimum for hPCFT vis ` vis RFC which parallels the pH microenvironments of solid tumors, and, most significantly, identification of the first small molecule cytotoxins that are selectively transported by hPCFT but not RFC. For analogs AG17, AG71, and AG94, in vitro cytotoxicities resulted from hPCFT transport and inhibition of de novo purine biosynthesis at glycinamide ribonucleotide formyltransferase. Another cytotoxic hPCFT substrate, AG112, was a potent inhibitor of thymidylate synthase. AG71 was tested in vivo against subcutaneous human hepatoma cells in SCID mice and showed potent hPCFT-targeted activity without significant toxicity. The goal of this project is to develop a new generation of potent tumor-targeted chemotherapy agents based on their selective capacities for cellular uptake by hPCFT over RFC. In aim 1, we will synthesize novel bicyclic and tricyclic analogs from 22 series of compounds, based on structure-activity profiles for AG17, AG71, AG94 and AG112, and molecular modeling with modifications of the ring systems, the linker domain, and the terminal glutamate. In aim 2, we test compounds from aim 1 for cytotoxicity in isogenic hamster and human tumor cell line models with established patterns of RFC and hPCFT expression, identify molecular targets by nucleoside protection, in situ metabolic labeling and analysis of intracellular metabolites, and studies with isolated enzymes. Additional studies will characterize transport properties of the novel analogs with hPCFT vis a vis RFC, and metabolism to polyglutamates. Finally, in aim 3, we will evaluate in vivo efficacies of the most potent hPCFT-targeted analogs by in vivo toxicity and efficacy trials in hPCFT-expressing human tumors implanted into SCID mice. Our results will define a comprehensive structure-activity relationship for transport by hPCFT vis a vis RFC and afford optimized analogs with potent and selective antitumor activities against hPCFT-expressing tumors in vitro and in vivo. This study will define mechanisms of action of the novel hPCFT-targeted cytotoxic analogs and potentially provide agents to be used clinically, albeit with a different spectrum of antitumor activities and reduced toxicities than those currently in use.
PUBLIC HEALTH RELEVANCE: This application explores potential therapeutic applications of human proton-coupled folate transporter (hPCFT), a recently discovered membrane transport system for folates and antifolates in many human tissues and solid tumors which is functionally and (to some degree) anatomically distinct from the ubiquitously expressed human reduced folate carrier (hRFC), the major tissue folate transport system in human cells and tissues, and the high affinity folate receptors (FRs). We hypothesize that hPCFT represents a novel and selective mechanism for therapeutic targeting small molecule cytotoxins which are not transported by other major (anti)folate transport systems, most notably hRFC. This concept is based on the frequent and high level hPCFT expression in many human solid tumors, the acidic pH optimum for hPCFT vis a vis hRFC which parallels the low pH microenvironments reported for solid tumors, and, most significantly, identification of first small molecule cytotoxins that are selectively transported by hPCFT but not hRFC (typified by compounds AG17, AG71, AG94, and AG112). An important goal of this application is to rationally develop specific transport substrates for hPCFT that will afford antitumor agents without toxicity to normal cells that primarily use hRFC for (anti)folate uptake. To our knowledge, this collaboration between an accomplished biochemist specializing in molecular pharmacology of anticancer drugs and an outstanding medicinal chemist with a demonstrated track record of antifolate drug design represents the only such endeavor capable of generating unique pharmacophores for all the therapeutically relevant (anti)folate transporters, including hRFC and hRFC, and FRs.
描述(由申请人提供):近年来,基于肿瘤选择性膜转运能力的叶酸治疗癌症再次受到重视。这项应用探索了人类质子偶联叶酸转运体(HPCFT)的治疗潜力,这是一种新近发现的叶酸和抗叶酸的膜转运系统,在功能和(某种程度上)解剖上与普遍表达的还原叶酸载体(RFC)不同,RFC是主要的组织叶酸转运体。我们假设hPCFT代表了一种新的和选择性的治疗靶向小分子细胞毒素的手段,这些小分子细胞毒素不是由RFC转运的。这一概念是基于hPCFT在许多实体肿瘤中频繁和高水平的表达,hPCFT相对于RFC的最适酸性pH与实体瘤的pH微环境平行,以及最重要的是,鉴定了第一批由hPCFT而不是RFC选择性转运的小分子细胞毒素。对于类似物AG17、AG71和AG94,体外细胞毒性是由于hPCFT转运和甘氨酰胺核糖核苷酸甲酰转移酶抑制从头合成嘌呤所致。另一种细胞毒性hPCFT底物AG112是胸苷合成酶的有效抑制物。在SCID小鼠体内测试AG71对皮下人肝癌细胞的作用,显示出强大的hPCFT靶向活性,没有明显的毒性。该项目的目标是开发新一代有效的肿瘤靶向化疗药物,其基础是hPCFT对细胞摄取的选择性能力高于RFC。在目标1中,我们将根据AG17、AG71、AG94和AG112的构效关系和分子模拟,通过对环系、连接域和末端谷氨酸的修饰,从22个系列的化合物中合成新型的双环和三环类似物。在目标2中,我们测试了来自目标1的化合物在同基因仓鼠和人类肿瘤细胞系模型中的细胞毒性,建立了RFC和hPCFT的表达模式,通过核苷保护、细胞内代谢物的原位代谢标记和分析以及分离的酶的研究来确定分子靶点。更多的研究将表征新型类似物hPCFT相对于RFC的转运特性,以及代谢到聚谷氨酸的特性。最后,在目标3中,我们将通过体内毒性和疗效试验来评估最有效的hPCFT靶向类似物的疗效,将hPCFT表达的人类肿瘤植入SCID小鼠体内。我们的结果将确定hPCFT相对于RFC转运的全面构效关系,并提供优化的类似物,在体外和体内对hPCFT表达的肿瘤具有有效和选择性的抗肿瘤活性。这项研究将确定新型hPCFT靶向细胞毒类似物的作用机制,并可能提供用于临床的药物,尽管其抗肿瘤活性和毒性与目前使用的不同。
与公共卫生相关:这项应用探索了人质子偶联叶酸转运体(HPCFT)的潜在治疗应用,hPCFT是最近发现的一种膜传输系统,用于在许多人体组织和实体肿瘤中运输叶酸和抗叶酸,它在功能和(某种程度)解剖上不同于普遍表达的人还原型叶酸载体(HRFC),HRFC是人类细胞和组织中主要的叶酸运输系统,以及高亲和力叶酸受体(FR)。我们假设,hPCFT代表了一种新的、选择性的治疗靶向小分子细胞毒素的机制,这些小分子细胞毒素不被其他主要的(抗)叶酸转运系统运输,最著名的是HRFC。这一概念是基于hPCFT在许多人类实体肿瘤中频繁和高水平的表达,hPCFT相对于HRFC的最适酸性pH与报道的实体肿瘤的低pH微环境平行,以及最重要的是,鉴定了第一批选择性转运hPCFT而不是HRFC的小分子细胞毒素(以化合物AG17、AG71、AG94和AG112为代表)。这一应用的一个重要目标是合理地开发hPCFT的特定转运底物,以提供对主要使用HRFC来(抗)叶酸摄取的正常细胞无毒性的抗肿瘤药物。据我们所知,一位擅长抗癌药物分子药理学的杰出生物化学家和一位在抗叶酸药物设计方面有良好记录的杰出药物化学家之间的合作,是唯一能够为包括HRFC和HRFC在内的所有治疗相关(抗)叶酸转运体和FRS产生独特药效的努力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEEM GANGJEE其他文献
ALEEM GANGJEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEEM GANGJEE', 18)}}的其他基金
Novel Cytoskeletal Stabilizers as Potential Treatments for Limbic Lewy Body Disorders
新型细胞骨架稳定剂作为边缘系统路易体疾病的潜在治疗方法
- 批准号:
10040472 - 财政年份:2020
- 资助金额:
$ 46.23万 - 项目类别:
Pneumocystis jirovecii Targeted Antiopportunistic Agents
耶氏肺孢子虫靶向抗机会药物
- 批准号:
8416314 - 财政年份:2012
- 资助金额:
$ 46.23万 - 项目类别:
Pneumocystis jirovecii Targeted Antiopportunistic Agents
耶氏肺孢子虫靶向抗机会药物
- 批准号:
8605505 - 财政年份:2012
- 资助金额:
$ 46.23万 - 项目类别:
Pneumocystis jirovecii Targeted Antiopportunistic Agents
耶氏肺孢子虫靶向抗机会药物
- 批准号:
8327441 - 财政年份:2012
- 资助金额:
$ 46.23万 - 项目类别:
Pneumocystis jirovecii Targeted Antiopportunistic Agents
耶氏肺孢子虫靶向抗机会药物
- 批准号:
8996110 - 财政年份:2012
- 资助金额:
$ 46.23万 - 项目类别:
Water Soluble Antimitotics That Circumvent Rumor Resistance
规避谣言抵抗的水溶性抗有丝分裂剂
- 批准号:
8450879 - 财政年份:2011
- 资助金额:
$ 46.23万 - 项目类别:
Water Soluble Antimitotics That Circumvent Rumor Resistance
规避谣言抵抗的水溶性抗有丝分裂剂
- 批准号:
8641327 - 财政年份:2011
- 资助金额:
$ 46.23万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 46.23万 - 项目类别:
Continuing Grant